An open, phase III, multicentre, 52-week study, evaluating the safety and efficacy of Symbicort Turbuhaler (1,2, and 4 x 160/4.5 microg twice daily) in Japanese patients with asthma.

Trial Profile

An open, phase III, multicentre, 52-week study, evaluating the safety and efficacy of Symbicort Turbuhaler (1,2, and 4 x 160/4.5 microg twice daily) in Japanese patients with asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Jan 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 22 Nov 2006 Status change
    • 28 Jul 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top